Remove companies revolution-medicines-inc
article thumbnail

Revolution Medicines Completes Acquisition of EQRx

Benzinga

Billion in Net Cash to Revolution Medicines' Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Board of Directors REDWOOD CITY, Calif., 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.

article thumbnail

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

Benzinga

08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. NASDAQ: RVMD ), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. About Revolution Medicines, Inc. About EQRx, Inc. REDWOOD CITY, Calif. and CAMBRIDGE, Mass.,

Equity 40